ClinicalTrials.gg
RecruitingNCT06124950Updated Aug 28, 2024

A Couple-based Gender-transformative Intervention on IPV Against Infertile Women

An interventional study of Gender-transformative intervention in Infertility, Female and Violence, Domestic, sponsored by Peking University Third Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-28.

Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
752
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Infertility, Female with a site in China — 17 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.

Planned enrollment
8th of 51
752 · median 178
Started
2024
with 3 others
No phase
32 of 58
12 open now
Primary completion
2026-07
later than 11 of 19 live
Registered
41st of 58
by date
Lead sponsor
6 of 58
Peking University Third Hospital

Among the 58 studies in Infertility, Female with a site in China, this one is the 8th largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2024, is one of 32 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 41st registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

17 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Infertility, Female with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label, randomized controlled trial conducted at two reproductive medicine centers in Beijing, China. Couples undergoing their first or second in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle, diagnosed with female-factor infertility, and who have signed informed consent will be enrolled. Exclusion criteria include couples receiving donated oocytes, sperm, or embryos; those diagnosed with severe male-factor infertility or unexplained infertility; those undergoing preimplantation genetic testing (PGT); those who have not undergone embryo transfer within six months after oocyte retrieval; those with severe mental disorders; and those who withdraw from the study.

Participants are will randomly allocated 1:1 by center to either the intervention or control group. Couples in the intervention group will receive five 60-minutes GTI sessions focusing on gender norms, gender equality, and healthy relationship skills, conducted by trained healthcare providers and social workers. The control group will receive standard reproductive care. A total of 376 infertile couples will be enrolled (188 couples per group).

The primary outcome is the IPV rate against infertile women over the past 12 months.

Read the detailed description

Infertility and intimate partner violence (IPV) are significant challenges in sexual and reproductive health, with a notable intersection as infertile women face higher IPV risks. However, the needs of infertile couples have been largely overlooked, and the effectiveness of gender-transformative interventions (GTIs) designed to challenge gender inequality and question gender norms in reducing IPV against infertile women has not been evaluated.

This is a multicenter, open-label, randomized controlled trial conducted at two reproductive medicine centers in Beijing, China (the Centers for Reproductive Medicine of Peking University Third Hospital and Beijing Obstetrics and Gynecology Hospital).

A multidisciplinary team of experts, including 8-10 experts in reproductive medicine, nursing, social work, psychiatry, family law, and evidence-based medicine, will be established to support the development of the intervention. Five 60-minutes GTI sessions will be delivered by trained nurses and social workers throughout participants' fertility treatment cycle. Intervention will be carried out at the 4 critical windows of opportunity for infertility treatment: (1) before entering the cycle; (2) during follicular monitoring; (3) the oocyte retrieval-embryo transfer phase; (4) 2 weeks after the embryo transfer (hCG pregnancy test), and (5) 28-30 days after the embryo transfer. The intervention components will equip couples with educational information on health and relationship and skills obtained from interactive activities designed with an explicit focus on challenging gender stereotypes, all of which could incite reflection on sociocultural norms and gender-related power inequality.

Participants are will randomly allocated 1:1 by center to either the intervention or control group. Couples in the intervention group will receive GTI sessions. The control group will receive standard reproductive care. A total of 376 infertile couples will be enrolled (188 couples per group).

03

Conditions studied

  • Infertility, Female
  • Violence, Domestic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Couples who are undergoing their first or second IVF/ICSI cycle;
  • Couples diagnosed with female-factor infertility;
  • Couples who have signed consent.

Exclusion criteria

Exclusion Criteria:

  • Couples who receive donated oocytes, sperm, or embryos;
  • Couples diagnosed with severe male-factor infertility or unexplained infertility.
  • Couples who are undergoing Preimplantation Genetic Testing (PGT);
  • Couples who have not undergone embryo transfer within six months after oocyte retrieval;
  • Couples who have severe mental disorders;
  • Couples who withdrew from the study.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
752 participants (estimated)

Study arms

  • Experimental
    GTI Intervention

    Participants in the intervention group will be provided with five GTI sessions (60-minutes/session) by trained nurses and social workers throughout participants' fertility treatment cycle throughout participants' fertility treatment cycle.

    Behavioral: Gender-transformative intervention

  • No intervention
    Standard Care

    Participants in the intervention group will be provided with standard clinical procedures for assisted reproduction and health education.

Interventions

  • BehavioralGender-transformative intervention

    A multidisciplinary team of experts, including 8-10 experts in reproductive medicine, nursing, social work, psychiatry, family law, and evidence-based medicine, will be established to support the development of the intervention. Five 60-minutes intervention sessions will be delivered by trained nurses and social workers throughout participants' fertility treatment cycle. Intervention will be carried out at the 5 critical windows of opportunity for infertility treatment: (1) before entering the cycle; (2) during follicular monitoring; (3) before oocyte retrieval; and (4) 2 weeks after the embryo transfer; and (5) 28-30 days after the embryo transfer. The intervention components will equip couples with educational information on health and relationship and skills obtained from interactive activities designed with an explicit focus on challenging gender stereotypes, all of which could incite reflection on sociocultural norms and gender-related power inequality.

06

What researchers measure

Primary outcomes

  1. Past-12-months Intimate Partner Violence against infertile women

    Past-12-months prevalence of IPV against infertile women measured using an instrument that combined the Revised Conflict Tactics Scale (CTS-2) and the Scale of Economic Abuse-12 (SEA-12). Respondents will be asked if they had experienced any specific acts of physical (6 items from CTS-2 injury subscale, 12 from CTS-2 physical assault subscale), psychological (8 items from CTS-2 psychological aggression subscale), sexual (7 items from CTS-2 sexual coercion subscale), or economic violence (12 items from SEA-12) in the past 12 months. The past-12-months prevalence of IPV is calculated as the proportion of participants reporting at least one act of violence in the past 12 months.

    Time frame: T0 (Baseline) and T0 + ~14 months (4 weeks after delivery)

Secondary outcomes

  1. Past-12-months Intimate Partner Violence against male partners

    Past-12-months prevalence of IPV against male partners measured using an instrument that combined the Revised Conflict Tactics Scale (CTS-2) and the Scale of Economic Abuse-12 (SEA-12). Respondents will be asked if they had experienced any specific acts of physical (6 items from CTS-2 injury subscale, 12 from CTS-2 physical assault subscale), psychological (8 items from CTS-2 psychological aggression subscale), sexual (7 items from CTS-2 sexual coercion subscale), or economic violence (12 items from SEA-12) in the past 12 months. The past-12-months prevalence of IPV is calculated as the proportion of participants reporting at least one act of violence in the past 12 months.

    Time frame: T0 (Baseline) and T0 + ~14 months (4 weeks after delivery)

  2. Past-3-months Intimate Partner Violence against infertile women

    Past-3-months prevalence of IPV against infertile women measured using the World Health Organization Violence Against Women (WHO-VAW) Instrument. The WHO-VAW has 6 items asking if participants had experienced any specific acts of physical (1 item), sexual (1 item), and psychological (4 items) violence in the past 3 months. The past-3-months prevalence of IPV is calculated as the proportion of participants reporting at least one act of violence in the past 3 months.

    Time frame: T0 (Baseline); T0 + ~2months (28-30 days after embryo transfer); T0 + ~4 months (12-13 weeks of gestation); T0 + ~12-14 months (4 weeks after delivery)

  3. Past-3-months Intimate Partner Violence against male partners

    Past-3-months prevalence of IPV against male partners measured using the World Health Organization Violence Against Women (WHO-VAW) Instrument. The WHO-VAW has 6 items asking if participants had experienced any specific acts of physical (1 item), sexual (1 item), and psychological (4 items) violence in the past 3 months. The past-3-months prevalence of IPV is calculated as the proportion of participants reporting at least one act of violence in the past 3 months.

    Time frame: T0 (Baseline); T0 + ~2months (28-30 days after embryo transfer); T0 + ~4 months (12-13 weeks of gestation); T0 + ~12-14 months (4 weeks after delivery)

  4. Past-12-months Severe Intimate Partner Violence against infertile women

    Past-12-months prevalence of severe IPV against infertile women measured using an instrument that combined the Revised Conflict Tactics Scale (CTS-2) and the Scale of Economic Abuse-12 (SEA-12). Respondents will be asked if they had experienced any specific acts of physical (6 items from CTS-2 injury subscale, 12 from CTS-2 physical assault subscale), psychological (8 items from CTS-2 psychological aggression subscale), sexual (7 items from CTS-2 sexual coercion subscale), or economic violence (12 items from SEA-12) in the past 12 months. Severe IPV is defined as any reported instance of physical or sexual violence (regardless of frequency) and/or any psychological or economic violence ≥ 3 times in the past year. The past-12-months prevalence of severe IPV is calculated as the proportion of participants reporting at least one severe IPV in the past 12 months.

    Time frame: T0 (Baseline) and T0 + ~14 months (4 weeks after delivery)

  5. Past-12-months severe Intimate Partner Violence against male partners

    Past-12-months prevalence of severe IPV against male partners measured using an instrument that combined the Revised Conflict Tactics Scale (CTS-2) and the Scale of Economic Abuse-12 (SEA-12). Respondents will be asked if they had experienced any specific acts of physical (6 items from CTS-2 injury subscale, 12 from CTS-2 physical assault subscale), psychological (8 items from CTS-2 psychological aggression subscale), sexual (7 items from CTS-2 sexual coercion subscale), or economic violence (12 items from SEA-12) in the past 12 months. Severe IPV is defined as any reported instance of physical or sexual violence (regardless of frequency) and/or any psychological or economic violence ≥ 3 times in the past year. The past-12-months prevalence of severe IPV is calculated as the proportion of participants reporting at least one severe IPV in the past 12 months.

    Time frame: T0 (Baseline) and T0 + ~14 months (4 weeks after delivery)

  6. Attitudes toward male gender roles

    Attitudes toward male gender roles measured by the Male Role Attitudes Scale (MRAS) to assess infertile couples' attitudes towards traditional male role stereotypes. The MRAS has 8 items. Responses to the MRAS were based on a four-point Likert scale from 'strongly disagree=1' to 'strongly agree=4'. A total score was derived by totalling responses to each item, giving a possible score of 8-32, where higher scores indicate greater endorsement of traditional male role stereotypes.

    Time frame: T0 (Baseline); T0 + ~2months (28-30 days after embryo transfer); T0 + ~4 months (12-13 weeks of gestation); T0 + ~12-14 months (4 weeks after delivery)

  7. Martial quality and satisfaction

    Martial quality and satisfaction measured by the Relationship Assessment Scale (RAS). The RAS has 7 items. Responses to the RAS were based on a five-point Likert scale from 'low=1' to 'high=5'. Items 4 and 7 are reverse-scored. A total score was derived by totalling responses to each item, giving a possible score of 7-35. The higher the score, the more satisfied the respondent is with his/her relationship.

    Time frame: T0 (Baseline); T0 + ~2months (28-30 days after embryo transfer); T0 + ~4 months (12-13 weeks of gestation); T0 + ~12-14 months (4 weeks after delivery)

  8. Couples' coping with stress

    Couples' coping with stress was measured by two items from the Dyadic Coping Inventory (DCI). Responses to the DCI were based on a five-point Likert scale ranging from 'strongly disagree = 1' to 'strongly agree = 5'.A total score was derived by totalling responses to each item, giving a possible score of 2-10. A higher score indicates couple's better dyadic coping with stress.

    Time frame: T0 (Baseline); T0 + ~2months (28-30 days after embryo transfer); T0 + ~4 months (12-13 weeks of gestation); T0 + ~12-14 months (4 weeks after delivery)

  9. Patient satisfaction with infertility treatment

    Patient satisfaction was measured by one item from the patient satisfaction survey. Responses to this question were based on a five-point Likert scale ranging from 'strongly disagree = 1' to 'strongly agree = 5'. The score ranged from 1 to 5, with a higher score indicating greater satisfaction with the infertility treatment.

    Time frame: T0 (Baseline); T0 + ~2months (28-30 days after embryo transfer); T0 + ~4 months (12-13 weeks of gestation); T0 + ~12-14 months (4 weeks after delivery)

  10. Human chorionic gonadotropin (hCG) Positive

    Positive for Beta-human chorionic gonadotropin (βhCG) in blood or urine after embryo transfer.

    Time frame: T0 + ~1.5 months

  11. Clinical pregnancy

    One or more observed gestational sac or definitive clinical signs of pregnancy under ultrasonography at 28-30 days after embryo transfer (including clinically documented ectopic pregnancy).

    Time frame: T0 + ~2 months (28-30 days after embryo transfer)

  12. Ongoing pregnancy

    Presence of a gestational sac and fetal heartbeat after 12 weeks of gestation.

    Time frame: T0 + ~4 months (12 weeks after embryo transfer)

  13. Miscarriage

    Spontaneous loss of an intra-uterine pregnancy prior to 22 completed weeks of gestational age.

    Time frame: 22 weeks of gestation

  14. Biochemical Pregnancy Loss

    Positive for hCG after embryo transfer, but no clinical pregnancy observed.

    Time frame: T0 + 1.5-2 months

  15. Stillbirth

    Fetal death after 22 weeks of gestation, with no signs of life such as heartbeat, breathing, umbilical cord pulse, or voluntary muscle contraction.

    Time frame: After 22 weeks of gestation

  16. Live birth

    A delivery of one or more living infants (≥22 weeks gestation or birth weight more than 1,000g).

    Time frame: After 22 weeks of gestation

  17. Ectopic pregnancy

    Implantation takes place outside the uterine cavity, confirmed by sonography or laparoscopy.

    Time frame: 7 weeks of gestation

  18. Cycle cancellation

    The cycle is considered canceled if any of the following situations occur from the ovarian stimulation to the embryo transfer: 1. The researcher determines that by the 20th day of ovarian stimulation, there are not ≥2 follicles with a diameter of ≥18mm. 2. Ultrasound reveals more than 25 follicles with a diameter of ≥12mm. 3. No oocytes are retrieved on the egg retrieval day. 4. No transferable embryos are available on the transfer day. 5. Ovarian Hyperstimulation Syndrome (OHSS) occurs during the ovarian stimulation process. 6. The participant requests to cancel the cycle or the researcher cancels the cycle for other valid reasons.

    Time frame: T0 + ~2 months

  19. Preterm birth

    Birth of a fetus delivered after 28 and before 37 completed weeks of gestational age in participants confirmed ongoing pregnancy.

    Time frame: 28-37 weeks of pregnancy

  20. Birth weight

    The weight measured for the first time within the first hour after birth. High birth weight: ≥4kg; Low birth weight: \< 2.5kg.

    Time frame: Within the first hour after live birth

  21. Congenital anomaly

    Any congenital anomaly will be included, including structural or chromosomal abnormalities of the fetus in utero, Trisomy 21 (Down syndrome), congenital heart disease, neural tube defects, cleft lip and palate, polydactyly, hydrocephalus, etc.

    Time frame: Within 2 weeks after live birth

  22. Neonatal mortality

    Death of a live born baby within 28 days of birth

    Time frame: Within 28 days of birth

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Given the nature of the study, individual participant data (IPD) will not be available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jul 2026, 25 months after the start.

Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 25 months is close to that.

Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Nov 9, 2023
StartActual
Jun 25, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Aug 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06124950
Collaborators
Beijing Obstetrics and Gynecology Hospital
Responsible party
Jie Qiao (Chief Physician, Peking University Third Hospital) — Principal investigator
First posted
Nov 9, 2023
Start date
Jun 25, 2024
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Aug 28, 2024

Study contacts

Yu Fu, MS
Contact
annyfy0417@gmail.com
+86 13521777668
Yuanyuan Wang, Dr
Contact
yyuanwang@163.com
+86 13811352300
Jie Qiao, Dr
principal investigator · Peking University Third Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion